Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000

Noveris seeks up to $500,000 via convertible debentures with 10% annual interest.

What the company is saying

Noveris Health Sciences Inc. is announcing its intention to raise up to $500,000 through a non-brokered private placement of convertible debentures. The company frames the offering as a straightforward financing, emphasizing the 10% annual interest rate and the ability for holders to convert after four months at a price not less than $0.05 per unit. Each unit includes one common share and one warrant, with warrants exercisable for 24 months at the greater of $0.05 or the 20-day VWAP. The company states the proceeds will be used for general working capital, administrative expenses, and research and development, but does not provide a breakdown or specific allocation. The announcement asserts that no change of control will result, but does not supply supporting details. The tone is matter-of-fact and avoids promotional language, focusing on the mechanics and timing of the proposed financing.

What the data suggests

The only concrete figures are the proposed $500,000 principal, 10% per annum interest, and conversion mechanics tied to a minimum $0.05 per unit price. No actual funds have been raised yet, and there is no evidence of investor commitments or closing progress. The maturity is 12 months from closing, but the closing itself is only expected on or about August 28, 2026, leaving the timeline open. There are no financial statements, cash flow data, or operational metrics disclosed, so the company’s current financial health and runway are unknown. The intended use of proceeds is stated in general terms without quantification or prioritization. The lack of detail on existing capitalization, burn rate, or how this financing fits into broader funding needs limits the ability to assess financial trajectory. All evidence provided relates solely to the structure of the proposed offering, not to realised business or financial progress.

Analysis

The announcement is a standard disclosure of an intended financing (private placement of convertible debentures) and outlines the terms, mechanics, and intended use of proceeds. The language is factual and does not overstate the impact or certainty of the offering; it simply describes the structure and timing. Most claims are forward-looking, as the offering has not yet closed and proceeds are not yet available, but there is no promotional or exaggerated language about future business outcomes or returns. No operational, revenue, or profitability metrics are disclosed, and there is no evidence of realised financial or operational progress. The gap between narrative and evidence is minimal, as the announcement does not attempt to inflate expectations beyond the facts presented.

Risk flags

• ●There is no evidence of investor commitments or subscription agreements, so the company may not raise the full $500,000 or any funds at all. This matters because operational plans and runway depend on successful closing.
• ●The use of proceeds is described only in broad categories—working capital, administrative expenses, and research and development—without specific amounts or milestones. This lack of detail makes it difficult for investors to assess how the capital will be allocated or whether it will drive measurable business progress.
• ●No financial statements, cash position, or burn rate are disclosed, so investors cannot assess whether the proposed raise is sufficient or how it fits into the company’s broader funding needs. This opacity increases financial risk.
• ●The assertion that no change of control will result is unsupported by share structure data, so investors cannot independently verify the impact of potential conversions and warrant exercises on ownership and governance.

Bottom line

This is an early-stage financing announcement with no evidence of funds raised or investor participation to date. The terms are standard for a microcap convertible debenture: 10% interest, 12-month maturity, and conversion/warrant mechanics tied to market pricing. The absence of financial statements, operational metrics, or a detailed use-of-proceeds plan means investors have no visibility into whether this capital will be sufficient or transformative. The company’s claim that no change of control will result is unsubstantiated without share structure data. Until the financing closes and actual deployment of funds is reported, there is no actionable signal beyond the intent to raise capital. The most important takeaway is that this is a proposed, not completed, financing, and the company’s financial trajectory remains opaque.

Announcement summary

(CSE: NVRS) Noveris Health Sciences Inc. is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000. The Offering is expected to close on or about August 28, 2026. The Debentures will bear interest at a rate of 10% per annum, payable in Common Shares on the date of conversion of the Debentures, and will mature 12 months from the Closing Date. At the option of the holder, at any time after the date that is four months from the Closing Date, the outstanding principal amount of the Debentures may be converted into units of the Company at a conversion price per Unit equal to the greater of $0.05 and the volume-weighted average trading price of the Common Shares on the Canadian Securities Exchange for the 20 trading days immediately preceding the applicable Conversion Date. Each Unit will be comprised of one common share of the Company and one common share purchase warrant of the Company. Each Warrant will entitle the holder to purchase one Common Share at an exercise price equal to the greater of $0.05 and the volume-weighted average trading price of the Common Shares on the CSE for the 20 trading days immediately preceding the applicable Conversion Date, for a period of 24 months commencing from the date of issuance. The Company intends to use the net proceeds of the Offering for general working capital, general and administrative expenses, and research and development.

Disagree with this article?